Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering

Group 1 - Curanex Pharmaceuticals Inc. has priced its initial public offering (IPO) of 3,750,000 shares at $4.00 per share, aiming for gross proceeds of $15 million [1] - The IPO is expected to close on August 27, 2025, and shares will begin trading on the Nasdaq Capital Market under the ticker symbol "CURX" [1] - Underwriters have an option to purchase an additional 562,500 shares within 45 days of the offering's close [1] Group 2 - Proceeds from the offering will be used for the development of the lead product candidate, Phyto-N, for ulcerative colitis, including FDA-required studies and IND application preparation [2] - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with Phyto-N being a botanical extract with proven anti-inflammatory properties [7][8] - Phyto-N has been validated in animal models for six inflammatory diseases, with the primary indication being moderate to severe ulcerative colitis [8] Group 3 - Dominari Securities LLC is the lead underwriter for the offering, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [3] - A registration statement for the offering was filed with the SEC and declared effective on August 12, 2025 [4] - The final prospectus related to the offering will be available on the SEC's website [4][5]